Pernix Therapeutics Hldgs buy klostergang
Zusammenfassung
Diese Einschätzung wurde am 07.12.15 mit einem Endkurs von 25,98 € beendet. Mit einer Rendite von -14,29 % entwickelte sich die Einschätzung BUY nicht nach Plan. klostergang hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
| Name | 1W | 1M | 1J | 3J |
|---|---|---|---|---|
| Pernix Therapeutics Hldgs | - | - | - | - |
| iShares Core DAX® | 0,36 % | -0,24 % | 3,83 % | 52,26 % |
| iShares Nasdaq 100 | 2,59 % | 1,79 % | 37,83 % | 92,38 % |
| iShares Nikkei 225® | 1,80 % | 7,12 % | 61,36 % | 79,73 % |
| iShares S&P 500 | 1,20 % | 0,93 % | 25,71 % | 66,15 % |
Kommentare von klostergang zu dieser Einschätzung
In der Diskussion Pernix Therapeutics Hldgs diskutieren
PTX is too cheap given its growth prospects and earnings trajectory!
Pernix Therapeutics (NASDAQ:PTX) is just one of a myriad small pharmaceuticals that have seen their stocks under pressure due to the fallout and collapse of Valeant Pharmaceuticals. After a big decline in its shares, the company reported blowout quarterly results this week.
At just $3.25 a share, the stock is too cheap given its growth prospects and earnings trajectory.
Earning Highlights: Pernix posted earnings of eight cents a share, seven cents a share above the consensus.Revenues climbed almost 55% year-over-year to just under $49 million for the quarter, just under $2 million above the consensus.Adjusted EBITDA increased to $8.7 million, compared to just under $7 million during the prior year period.
The company has three core products, Silenor, Treximit and Zohydro, that all have good growth prospects and decent patent expirations.